iRhythm vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

iRhythm Technologies Inc (IRTC)

Q3 202616 Jul – 2 Oct 2026

▲2▼2

iRhythm raises guidance and settles lawsuit, but cyberattack and a slashed target weigh

Q2 beat and raised 2026 guidance iRhythm's second-quarter sales rose about 20% to $224 million, profit beat expectations, and the company lifted full-year 2026 revenue guidance to $880–$890 million. More sales and a better outlook make future profits look larger, which supports a higher stock price.
The raised guidance and earnings beat are the core new positive force on the stock.
$45 million settlement eases legal overhang iRhythm proposed a $45 million settlement of the securities class action over its Zio AT monitor disclosures. Putting a price on a long-running legal risk removes uncertainty that had been hanging over the stock, which investors generally treat as a plus.
The proposed settlement is a new event that reduces a known legal risk.
Cyberattack exposed patient data iRhythm said a June cyberattack accessed patient names, contact details, birth dates and insurance numbers, and it is notifying those affected. Even though the company says operations and finances are unaffected, a health-data breach can bring regulatory scrutiny and reputational damage, weighing on the stock.
The data breach is a new negative event with potential regulatory and reputational cost.
Truist's drastic price-target cut Truist cut its iRhythm price target to $18 from $160, a huge reduction that overshadowed the strong earnings and guidance raise. A big analyst target cut signals doubt about the company's value and can push the stock down even when results are good.
The sharp target cut is a new negative signal that offset the good earnings news.

August 202616 Jul – 2 Oct 2026

▲2▼2

iRhythm raises guidance and settles lawsuit, but cyberattack and a slashed target weigh

Q2 beat and raised 2026 guidance iRhythm's second-quarter sales rose about 20% to $224 million, profit beat expectations, and the company lifted full-year 2026 revenue guidance to $880–$890 million. More sales and a better outlook make future profits look larger, which supports a higher stock price.
The raised guidance and earnings beat are the core new positive force on the stock.
$45 million settlement eases legal overhang iRhythm proposed a $45 million settlement of the securities class action over its Zio AT monitor disclosures. Putting a price on a long-running legal risk removes uncertainty that had been hanging over the stock, which investors generally treat as a plus.
The proposed settlement is a new event that reduces a known legal risk.
Cyberattack exposed patient data iRhythm said a June cyberattack accessed patient names, contact details, birth dates and insurance numbers, and it is notifying those affected. Even though the company says operations and finances are unaffected, a health-data breach can bring regulatory scrutiny and reputational damage, weighing on the stock.
The data breach is a new negative event with potential regulatory and reputational cost.
Truist's drastic price-target cut Truist cut its iRhythm price target to $18 from $160, a huge reduction that overshadowed the strong earnings and guidance raise. A big analyst target cut signals doubt about the company's value and can push the stock down even when results are good.
The sharp target cut is a new negative signal that offset the good earnings news.

Latest16 Jul – 2 Oct 2026

▲2▼2

iRhythm raises guidance and settles lawsuit, but cyberattack and a slashed target weigh

Q2 beat and raised 2026 guidance iRhythm's second-quarter sales rose about 20% to $224 million, profit beat expectations, and the company lifted full-year 2026 revenue guidance to $880–$890 million. More sales and a better outlook make future profits look larger, which supports a higher stock price.
The raised guidance and earnings beat are the core new positive force on the stock.
$45 million settlement eases legal overhang iRhythm proposed a $45 million settlement of the securities class action over its Zio AT monitor disclosures. Putting a price on a long-running legal risk removes uncertainty that had been hanging over the stock, which investors generally treat as a plus.
The proposed settlement is a new event that reduces a known legal risk.
Cyberattack exposed patient data iRhythm said a June cyberattack accessed patient names, contact details, birth dates and insurance numbers, and it is notifying those affected. Even though the company says operations and finances are unaffected, a health-data breach can bring regulatory scrutiny and reputational damage, weighing on the stock.
The data breach is a new negative event with potential regulatory and reputational cost.
Truist's drastic price-target cut Truist cut its iRhythm price target to $18 from $160, a huge reduction that overshadowed the strong earnings and guidance raise. A big analyst target cut signals doubt about the company's value and can push the stock down even when results are good.
The sharp target cut is a new negative signal that offset the good earnings news.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 202625 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest25 Jul – 23 Aug 2026

▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.
Explains the main force behind the stock's slump and why investors are worried.
Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.
Shows concrete capital actions that counter the negative news and support the stock.
First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.
This is the key new evidence that the business is recovering, directly answering why the stock may be moving.
Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.
Shows new product momentum that could drive future growth, a fresh positive for the stock.